Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + BCG in High-Risk NMIBC
NCT05580354Phase 4Unknown
- Sponsor
- Ruijin Hospital
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Ruijin Hospital. Primary endpoint: Relapse-Free Survival at 12 months. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05580354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580354.